FDA Brief

Warning letters Devices

FDA warning letter to

Globus Medical, Inc.

High riskIssued Jul 15, 2024Posted Aug 13, 2024Office of Medical Device and Radiological Health Division I

FDA warns Globus Medical over Excelsius GPS robot-related misplaced screw complaints and late or missing device reports.

What happened

FDA inspected the firm from February 15, 2024, through March 7, 2024, and found quality-system violations. It found repeated misplaced-screw complaints for the Excelsius GPS surgical robot were not properly analyzed for corrective action, and complaint investigations were inadequate, including one involving a patient death. FDA also found Medical Device Reporting (MDR) reports were late, misclassified, or missing, and electronic acknowledgments were not maintained.

What FDA found

  1. FDA found the company did not start corrective and preventive action (CAPA) investigations when complaints showed repeated misplaced screws, and its trend analysis lacked appropriate statistics and risk evaluation.

    21 CFR 820.100(a)(1)
  2. FDA found complaint investigations were not comprehensive, including a patient death complaint and a missed pedicle screw complaint.

    21 CFR 820.198(c)
  3. FDA says a serious injury from damage to the spinal cord’s dural lining was reported late and incorrectly classified as a malfunction.

    21 CFR 803.50(a)(1)
  4. FDA says several complaints about misplaced screws were reportable malfunctions, but the reports were late or not received.

    21 CFR 803.50(a)(2)
  5. FDA found the company could not provide FDA electronic acknowledgments for several MDR submissions.

    21 CFR 803.18(b)(1)(iii)

What FDA wants

FDA asks the company to notify it in writing within 15 business days of steps taken, planned corrections, documentation, and a timetable for any work that will take longer.

Who should pay attention

  • hospitals and surgeons using the Excelsius GPS surgical robot
  • medical device makers with complaint-handling and MDR reporting duties
  • quality teams that use complaint trends to decide on CAPA

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  4. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk